Fig. 2.

The Kaplan–Meier survival curves plotted for patients with pancreatic cancer, NSCLC, and prostate cancer with poor prognoses. G1 groups of patients treated with standard chemotherapy; G2 groups of patients treated with standard chemotherapy and an induction regimen of antiangiogenic and antitumor immunity agents. Mean survival is significantly longer for G2 than for G1 for patients with the three primary malignancies analyzed: 18.0 versus 10.2 months (log-rank, p = 0.036), 16.7 versus 12.1 months (log-rank, p = 0.042), and 20.4 versus 16.8 months (log-rank, p = 0.048) for pancreatic cancer, NSCLC, and prostate cancer, respectively